Sign in

You're signed outSign in or to get full access.

EH

enGene Holdings Inc. (ENGN)·Q2 2024 Earnings Summary

Executive Summary

  • enGene remains clinical-stage with no product revenue; Q2 2024 net loss was $14.98M and diluted EPS was -$0.38 as operating expenses increased with pivotal LEGEND scale-up and public company costs .
  • Guidance tightened: preliminary/interim LEGEND Cohort 1 data by end of September 2024, cash runway into 2027, and BLA timing targeted for mid-2026 .
  • Strategic expansion of LEGEND: adding a papillary-only cohort (target 70–100 patients) and modifying the second cohort to separately analyze BCG‑naïve vs BCG‑exposed; the company deprioritized EG‑i08 in cystic fibrosis to focus on bladder indications .
  • Near-term stock catalyst: publication of interim LEGEND data by end of September 2024, with management touting a differentiated ease‑of‑use profile designed for community urologists .

What Went Well and What Went Wrong

  • What Went Well

    • Funded into 2027 post February PIPE; July 31 cash was $257.7M, April 30 cash was $264.8M, supporting execution of pivotal LEGEND and expanded cohorts .
    • Clear clinical timeline: interim LEGEND BCG‑unresponsive data by end of September 2024; papillary‑only cohort expansion with Q4 2024 enrollment start; BLA timeline mid‑2026 .
    • Management messaging on product profile: “We believe the design of EG‑70, with its ease‑of‑use and non‑viral profile, positions it well to seamlessly slot into the standard of care” — Jason Hanson, CEO . “EG‑70 is designed to be a practice‑changing product that does not require a change in practice for urologists” — Dr. Gordon Brown (AUA) .

  • What Went Wrong

    • Operating expenses rose materially YoY and QoQ as clinical and manufacturing activity and G&A scaled; Q2 OpEx $17.3M vs $10.8M in Q1 and $4.7M in prior‑year Q2 .
    • Cohort enrollment pause: enrollment in the second LEGEND cohort temporarily paused pending cohort modification and expected FDA engagement; resumption expected in Q4 2024 .
    • Pipeline narrowing: EG‑i08 cystic fibrosis program deprioritized to prioritize bladder indications, reducing optionality outside GU oncology near‑term .

Financial Results

MetricQ2 2023 (YoY)Q1 2024 (Prior Q)Q2 2024 (Current)
Revenue ($USD Millions)$0.00 $0.00 $0.00
R&D Expense ($USD Millions)$1.52 $5.64 $9.86
G&A Expense ($USD Millions)$1.52 $5.14 $7.46
Total Operating Expenses ($USD Millions)$4.74 $10.77 $17.31
Net Loss ($USD Millions)$5.28 $10.74 $14.98
Diluted EPS ($USD)-$9.30 -$0.46 -$0.38
Weighted Avg Shares (Millions)0.69 23.20 39.44
Net Income Margin %N/A (no revenue) N/A (no revenue) N/A (no revenue)

Segment breakdown:

Operating SegmentDescription
Single segmentCompany operates as one segment focused on research, discovery, and clinical development of gene therapies

KPIs:

KPIQ1 2024Q2 2024
Cash and Cash Equivalents ($USD Millions)$85.65 $264.81
Total Assets ($USD Millions)$93.42 $273.53
Total Liabilities ($USD Millions)$31.04 $30.56
Shareholders’ Equity ($USD Millions)$93.42 $242.97

Drivers and cross-references:

  • OpEx growth driven by manufacturing and clinical costs for pivotal LEGEND and public company scaling (legal, accounting, audit, D&O insurance) .
  • Other income improved due to interest income on larger cash balances post PIPE .

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Interim LEGEND Cohort 1 data (BCG-unresponsive)2024 timing“Mid‑2024” “By end of September 2024” Clarified/tightened timing
BLA filing for EG‑70Mid‑2026“Q1 2026” “Mid‑2026” Pushed back slightly
LEGEND Cohort 3 (papillary-only Ta/T1)Enrollment start“New indication plans in H1 2024” Cohort added; target 70–100 patients; begin Q4 2024 Raised scope/added cohort
LEGEND Cohort 2 (BCG-naïve vs BCG‑exposed)Enrollment/resumption“Initial efficacy H2 2024 in BCG‑naïve cohort” Enrollment temporarily paused; modify to separately analyze BCG‑naïve vs BCG‑exposed; resume Q4 2024 Modified design; timing adjusted
Cash runwayThrough 2027“Into 2027” “Into 2027” Maintained
Pipeline prioritizationn/aNot disclosed EG‑i08 cystic fibrosis deprioritized Lowered focus outside bladder

Earnings Call Themes & Trends

Note: No Q2 2024 earnings call transcript was furnished; themes compiled from Q1 and Q2 press releases and Q2 10‑Q.

TopicPrevious Mentions (Q1 2024)Current Period (Q2 2024)Trend
Clinical milestonesInterim LEGEND mid‑2024; initial efficacy from BCG‑naïve H2 2024 Interim LEGEND by end of September 2024; cohort 2 modified; papillary-only cohort added Milestones clarified; program expanded
Product performancePhase 1 CR 73% at any time; RP2D subgroup CR 70% (3 mo) / 60% (6 mo) cited at AUA Corporate presentation reiterates clinical rationale and Phase 1 signals; ease‑of‑use highlighted Narrative consistent; emphasis on usability
R&D executionR&D up with CMC and clinical costs R&D up further on pivotal study/manufacturing scale‑up Continued ramp
Regulatory pathBLA Q1 2026 BLA mid‑2026 Slightly later timing
Organization/leadershipAdded SVP Urologic Oncology (Raj Pruthi) Board additions in May; continued build‑out for commercialization Strengthening capabilities
Supply chain/tariffs/macroNot discussed Not discussed No change

Management Commentary

  • “Our planned initial expansion of the LEGEND study will include a cohort focused on enrollment of patients with high‑risk, BCG‑unresponsive papillary‑only NMIBC… We plan to provide the interim data for the LEGEND BCG‑unresponsive cohort by the end of September 2024.” — Jason Hanson, CEO .
  • “I am pleased to present a detailed overview of EG‑70… designed to be a practice‑changing product that does not require a change in practice for urologists.” — Dr. Gordon Brown (AUA presentation) .
  • “Promising initial efficacy and safety data… combined with its ease of handling, simplicity of administration, minimal storage requirements, and lack of post‑procedural patient restrictions…” — Dr. Richard Bryce, CMO .

Q&A Highlights

  • The company furnished a Q2 press release and corporate presentation; an earnings call transcript was not furnished for Q2 in SEC filings, so no Q&A highlights are available. Management clarified timelines and cohort plans via press materials .

Estimates Context

  • Wall Street consensus EPS and revenue for Q2 2024 via S&P Global were unavailable at time of retrieval due to data access limits; therefore, estimate comparisons are not provided. Values would be retrieved from S&P Global when available.

Key Takeaways for Investors

  • Cash runway into 2027 reduces near‑term financing risk and supports pivotal execution and cohort expansion .
  • Interim LEGEND data by end of September 2024 is the key near‑term catalyst likely to drive stock volatility and estimate revisions .
  • Strategic focus on bladder indications with papillary‑only cohort (70–100 patients) broadens potential addressable population while aligning with ease‑of‑use positioning for community urologists .
  • Operating expense growth reflects accelerated CMC/clinical activity and public company costs; monitor OpEx discipline alongside clinical progress .
  • BLA timing shifted to mid‑2026; investors should calibrate timelines and probability of success accordingly .
  • Cohort 2 enrollment pause/modification signals proactive regulatory/scientific alignment; watch for resumption in Q4 2024 .
  • No product revenue; valuation remains catalyst‑driven with clinical efficacy/durability, safety, and usability profile versus alternatives (e.g., viral therapies) as differentiation points .

Appendix: Additional Quarter Reference

  • Q3 2024 (subsequent): Cash $257.7M; OpEx $16.8M; diluted EPS -$0.32; company reiterated preliminary LEGEND data timing in September .